Literature DB >> 3571438

Norethisterone treatment to control timing of the IVF cycle.

P G Wardle, P A Foster, J D Mitchell, E A McLaughlin, J A Williams, E Corrigan, B D Ray, A McDermott, M G Hull.   

Abstract

The use of norethisterone to control the timing of the preceding menstrual cycle and in consequence the timing of the in-vitro fertilization (IVF) cycle has been evaluated in a therapeutic IVF programme in which oocyte recovery was limited to 2 days each week. A consecutive series of 181 cycles after norethisterone and 29 untreated controls were compared. Menstruation occurred 2-3 days after norethisterone as planned in 82% of patients overall and in 87% of patients whose menstrual cycle length varied by no more than 2 days about the median. Norethisterone treatment did not significantly affect the outcome of IVF treatment compared with the controls in respect to cycles abandoned (12 versus 0%, respectively), peak follicular diameter (mean 18.1 mm versus 18.3 mm 48 h before laparoscopy), oocyte recovery rate (4.6 versus 4.5 per patient), oocyte morphology (63% versus 52% mature), or fertilization rate (72 versus 65% of mature oocytes). Clinical pregnancies were too few for comparison (rates 27 versus 9% per laparoscopy) but the overall rate (23%) indicated effectiveness of the methods. Prior norethisterone treatment appears to be an effective and useful means of controlling the timing of the oocyte recovery in IVF treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3571438     DOI: 10.1093/oxfordjournals.humrep.a136454

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Efficiency and cost effectiveness of three protocols for gamete transfer.

Authors:  S G Awadalla; G W Randall
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-12

2.  In vitro fertilization programmed for weekday-only oocyte harvest: analysis of outcome based on actual retrieval day.

Authors:  A Ben-Chetrit; S Senoz; E M Greenblatt
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

3.  Mother-daughter in vitro fertilization triplet surrogate pregnancy.

Authors:  M C Michelow; J Bernstein; M J Jacobson; J L McLoughlin; D Rubenstein; A I Hacking; S Preddy; I J Van der Wat
Journal:  J In Vitro Fert Embryo Transf       Date:  1988-02

Review 4.  The state of "freeze-for-all" in human ARTs.

Authors:  Natalia Basile; Juan A Garcia-Velasco
Journal:  J Assist Reprod Genet       Date:  2016-09-14       Impact factor: 3.412

5.  In vitro fertilisation in a small unit in the NHS.

Authors:  P Bromwich; A Walker; S Kennedy; M Wiley; D Little; C Ross; I Sargent; J Bellinger; H O'Reilly; A Lopez-Bernal
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12

Review 6.  IVF, GIFT et al.

Authors:  D H Barlow
Journal:  J R Soc Med       Date:  1988-11       Impact factor: 18.000

7.  Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial.

Authors:  Erik E Hauzman; Azucena Zapata; Alfonso Bermejo; Carlos Iglesias; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Reprod Biol Endocrinol       Date:  2013-09-28       Impact factor: 5.211

8.  Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT.

Authors:  Ensieh Shahrokh Tehrani Nejad; Fatemeh Bakhtiari Ghaleh; Bita Eslami; Fedyeh Haghollahi; Maryam Bagheri; Masoumeh Masoumi
Journal:  Int J Reprod Biomed       Date:  2018-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.